Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLXNASDAQ:ARVNNASDAQ:BDTXNYSE:DNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$5.31-0.9%$4.31$1.58▼$7.27$473.34M-0.61.22 million shs906,493 shsARVNArvinas$6.51+0.6%$7.48$5.90▼$36.20$475.17M2.211.34 million shs1.24 million shsBDTXBlack Diamond Therapeutics$2.01-2.4%$1.63$1.20▼$6.75$114.30M2.631.50 million shs717,264 shsDNAGinkgo Bioworks$6.99+2.0%$7.21$5.00▼$27.16$409.14M1.291.46 million shs1.03 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals-0.93%+9.71%+4.94%+60.91%+190.16%ARVNArvinas+0.62%+0.31%-28.44%-63.37%-81.89%BDTXBlack Diamond Therapeutics-2.43%+3.08%+27.22%-6.94%-60.12%DNAGinkgo Bioworks+1.94%-11.76%-7.91%-35.61%-80.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMLXAmylyx Pharmaceuticals3.2945 of 5 stars3.62.00.00.02.64.21.3ARVNArvinas3.5005 of 5 stars4.33.00.00.02.02.51.3BDTXBlack Diamond Therapeutics3.1686 of 5 stars3.53.00.00.03.02.51.3DNAGinkgo Bioworks1.1007 of 5 stars0.83.00.00.02.82.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 3.13Buy$9.8385.19% UpsideARVNArvinas 2.60Moderate Buy$20.92221.30% UpsideBDTXBlack Diamond Therapeutics 3.00Buy$14.60626.37% UpsideDNAGinkgo Bioworks 1.67Reduce$5.77-17.50% DownsideCurrent Analyst Ratings BreakdownLatest BDTX, AMLX, ARVN, and DNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/14/2025AMLXAmylyx PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$7.00 ➝ $8.005/9/2025AMLXAmylyx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $16.005/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/7/2025AMLXAmylyx PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $10.005/6/2025AMLXAmylyx PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/5/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.505/5/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.005/5/2025ARVNArvinasTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$21.00 ➝ $11.005/2/2025ARVNArvinasBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$16.005/2/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $19.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals-$1.27M-372.12$0.96 per share5.51$6.42 per share0.83ARVNArvinas$426.90M1.11N/AN/A$8.17 per share0.80BDTXBlack Diamond Therapeutics$70M1.63N/AN/A$2.26 per share0.89DNAGinkgo Bioworks$237.42M1.72N/AN/A$21.93 per share0.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals$49.27M-$3.11N/AN/AN/AN/A-36.97%-29.61%N/AARVNArvinas-$198.90M-$0.66N/AN/AN/A-75.51%-33.75%-16.75%7/29/2025 (Estimated)BDTXBlack Diamond Therapeutics-$82.44M$0.06N/AN/AN/AN/A-68.08%-49.65%8/5/2025 (Estimated)DNAGinkgo Bioworks-$892.87M-$9.16N/AN/AN/A-298.78%-58.54%-34.24%N/ALatest BDTX, AMLX, ARVN, and DNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025AMLXAmylyx Pharmaceuticals-$0.45-$0.42+$0.03-$0.42N/AN/A5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A3/6/2025Q4 2024BDTXBlack Diamond Therapeutics-$0.31-$0.28+$0.03-$0.28N/AN/A3/4/2025Q4 2024AMLXAmylyx Pharmaceuticals-$0.49-$0.55-$0.06-$0.55N/A($0.67) millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx Pharmaceuticals$1.0219.13%N/AN/A N/AARVNArvinasN/AN/AN/AN/AN/ABDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A4.554.55ARVNArvinasN/A4.644.64BDTXBlack Diamond TherapeuticsN/A5.555.55DNAGinkgo BioworksN/A5.795.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%ARVNArvinas95.19%BDTXBlack Diamond Therapeutics95.47%DNAGinkgo Bioworks78.63%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals11.70%ARVNArvinas4.73%BDTXBlack Diamond Therapeutics8.87%DNAGinkgo Bioworks9.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals20089.14 million60.53 millionOptionableARVNArvinas42072.99 million65.18 millionOptionableBDTXBlack Diamond Therapeutics9056.86 million51.57 millionOptionableDNAGinkgo Bioworks64058.53 million51.89 millionOptionableBDTX, AMLX, ARVN, and DNA HeadlinesRecent News About These CompaniesGinkgo Bioworks appoints Steven Coen as new CFOMay 23 at 10:37 AM | uk.investing.comGinkgo Bioworks: Cost-Cutting Efforts Aren't EnoughMay 23 at 10:37 AM | seekingalpha.comOMERS ADMINISTRATION Corp Buys Shares of 34,800 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)May 22 at 4:23 AM | marketbeat.comGinkgo Bioworks Promotes Coen to CFO, Succeeding DmytrukMay 21 at 6:00 PM | marketwatch.comThis Startup Is Using Ancient DNA to Recreate Perfumes from Extinct FlowersMay 21 at 6:00 PM | msn.comGinkgo Bioworks Announces Appointment of Steven Coen as Chief Financial OfficerMay 21 at 4:19 PM | prnewswire.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) is a favorite amongst institutional investors who own 56%May 19, 2025 | finance.yahoo.com23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.May 19, 2025 | businessinsider.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Acquired by Bank of America Corp DEMay 18, 2025 | marketbeat.comBNP Paribas Financial Markets Increases Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)May 18, 2025 | marketbeat.comBalyasny Asset Management L.P. Acquires 59,334 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)May 17, 2025 | marketbeat.comApplied DNA Reports Second Quarter Fiscal 2025 Financial ResultsMay 15, 2025 | accessnewswire.comIMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19May 15, 2025 | globenewswire.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Acquired by Barclays PLCMay 11, 2025 | marketbeat.comCoastal Bridge Advisors LLC Grows Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)May 10, 2025 | marketbeat.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Caption Management LLCMay 10, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Acquires Shares of 101,881 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)May 10, 2025 | marketbeat.comGinkgo Bioworks Holdings, Inc. (DNA): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside PotentialMay 10, 2025 | finance.yahoo.comGinkgo Bioworks Holdings, Inc. (DNA): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside PotentialMay 9, 2025 | uk.finance.yahoo.comTwist Bioscience and Ginkgo Bioworks update 2022 partnershipMay 8, 2025 | msn.comTwist Bioscience and Ginkgo Bioworks Revise CollaborationMay 8, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDTX, AMLX, ARVN, and DNA Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$5.31 -0.05 (-0.93%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.20 -0.11 (-2.17%) As of 05/23/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Arvinas NASDAQ:ARVN$6.51 +0.04 (+0.62%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$6.50 -0.01 (-0.15%) As of 05/23/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Black Diamond Therapeutics NASDAQ:BDTX$2.01 -0.05 (-2.43%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.06 +0.05 (+2.44%) As of 05/23/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Ginkgo Bioworks NYSE:DNA$6.99 +0.14 (+2.04%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$7.06 +0.07 (+0.99%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
